The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this therapy for elderly patients aged ≥75 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Taki, Shinya, Tamai, Hideyuki, Ida, Yoshiyuki, Shingaki, Naoki, Kawashima, Akira, Shimizu, Ryo, Moribata, Kosaku, Maekita, Takao, Iguchi, Mikitaka, Kato, Jun, Nakao, Taisei, Kitano, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753689/
https://www.ncbi.nlm.nih.gov/pubmed/28798288
http://dx.doi.org/10.5009/gnl17048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753689/
https://www.ncbi.nlm.nih.gov/pubmed/28798288
http://dx.doi.org/10.5009/gnl17048

Ejemplares similares